Spark Therapeutics Sets Price Of Blindness-Treating Gene Therapy At $850,000

A new drug, Luxturna, literally allows blind people to see. It does it by using a virus to insert new genes into patients ’ eyes. This morning, Luxturna’s maker, Spark Therapeutics, is announcing the cost of this medical miracle: $425,000 per eye, or $850,000 a year.

Source: Forbes.com Healthcare News - January 3, 2018 Category: Pharmaceuticals Authors: Matthew Herper, Forbes Staff Tags: NASDAQ:ONCE NASDAQ:IONS NASDAQ:BIIB NASDAQ:ALXN Source Type: news